<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667963</url>
  </required_header>
  <id_info>
    <org_study_id>RIS protocol number 33593</org_study_id>
    <nct_id>NCT03667963</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Variation in Starch-digesting Enzymes on Digestibility and Glycemic Index of Cold and Hot Rice</brief_title>
  <official_title>Effect of Genetic Variation in Starch-digesting Enzymes on Digestibility and Glycemic Index of Rice Prepared in Different Ways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of different methods of preparation (cooked and consumed hot
      vs cooked, cooled overnight and consumed cold) and variation in the activity of salivary
      amylase on the glycemic index and carbohydrate digestibility in healthy human subjects. The
      effect of genetic variation in small intestinal starch digesting enzymes on glycemic index
      and starch digestibility will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Index (GI)</measure>
    <time_frame>0-2 hours</time_frame>
    <description>For each subject, the incremental area under the glucose response curve over 2 hours (iAUC) after each rice test meal is expressed as a percentage of the mean iAUC elicited by the 2 glucose test meals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate malabsorbed</measure>
    <time_frame>0-6 hours.</time_frame>
    <description>For each test meal the sum of breath hydrogen concentrations from the lowest value over 0-3 hours to 6 hours (termed &quot;H&quot;). For each subject the amount of hydrogen per gram malabsorbed carbohydrate (H/g) is calculated as (GL-G)/10 where GL is H after the glucose plus lactose meal and G is H after the glucose meal. The amount of carbohydrate malabsorbed after the hot and cold rice meals, respectively, are HR/Hg and CR/Hg, where HR and Cr are H after the hot and cold rice meals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic response</measure>
    <time_frame>0-2 hours</time_frame>
    <description>The incremental area under the blood glucose response curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath hydrogen response</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Sum of breath hydrogen concentrations from the lowest in the first 3 hours to 6 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Carbohydrate Intolerance</condition>
  <arm_group>
    <arm_group_label>Low Salivary Amylase Activity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Glucose Glucose plus lactulose Hot Rice Cold Rice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Salivary Amylase Activity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Glucose Glucose plus lactulose Hot Rice Cold Rice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>50g glucose dissolved in 250ml water</description>
    <arm_group_label>High Salivary Amylase Activity</arm_group_label>
    <arm_group_label>Low Salivary Amylase Activity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose plus lactulose</intervention_name>
    <description>50g glucose plus 10g lactulose dissolved in 250ml water</description>
    <arm_group_label>High Salivary Amylase Activity</arm_group_label>
    <arm_group_label>Low Salivary Amylase Activity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot Rice</intervention_name>
    <description>Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.</description>
    <arm_group_label>High Salivary Amylase Activity</arm_group_label>
    <arm_group_label>Low Salivary Amylase Activity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Rice</intervention_name>
    <description>Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.</description>
    <arm_group_label>High Salivary Amylase Activity</arm_group_label>
    <arm_group_label>Low Salivary Amylase Activity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females aged 18-75 years and in good health

          -  Eligible to receive income in Canada

          -  Have Ontario Health Insurance Plan or equivalent medical coverage.

          -  Previous donor of saliva using protocol reference number # 31093 or GIL-1670 (in which
             subject consents to measurement of salivary amylase activity and genetic variation in
             AMY1, SI and MGAM genes).

          -  Salivary amylase activity in the lowest tertile (&lt;50 U/ml) or highest tertile (&gt;105
             U/ml) of salivary amylase activity of 40 subjects previously measured.

        Exclusion Criteria:

          -  known history of AIDS, hepatitis, diabetes or a heart condition

          -  Allergy to rice, canola oil or sesame oil.

          -  use of medications (including, but not limited to, insulin or other antidiabetic
             drugs, systemic steroids, antipsychotics, protease inhibitors, antivirals,
             immunosuppressive agents and drugs affecting gut motility or digestion) or with any
             condition which might, in the opinion of Dr. Wolever, the Medical Director or GI Labs,
             either: 1) make participation dangerous to the participant himself (or herself) or to
             others, or 2) affect the results.

          -  individuals who cannot or will not comply with the experimental procedures or do not
             follow the instructions of GI Labs staff related to the safe performance of the
             experimental procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas MS Wolever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President, Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycemic Index Laboratories</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Thomas Wolever</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

